IMARC Group, a leading market research company, has recently released a report titled “Drug-Eluting Stents Market Report by Coating (Polymer Based Coating, Polymer Free Coating), Drug (Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, and Others), Stent Platform (Stainless-steel, Cobalt-Chromium, Platinum-Chromium, Nitinol, and Others), Generation (1st Generation, 2nd Generation, 3rd Generation, 4th Generation), Application (Coronary Artery Disease, Peripheral Artery Disease), End User (Hospitals, Ambulatory Surgical Centers, and Others), and Region 2024-2032”. The study provides a detailed analysis of the industry, including the global drug-eluting stents market share, size, trends and growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
The global drug-eluting stents market size reached US$ 8.3 Billion in 2023. Looking forward, the market is expected to reach US$ 13.7 Billion by 2032, exhibiting a growth rate (CAGR) of 5.51% during 2024-2032.
Request to Get the Sample Report: https://www.imarcgroup.com/drug-eluting-stents-market/requestsample
Factors Affecting the Growth of the Drug-Eluting Stents Industry:
- Rising Prevalence of Cardiovascular Diseases:
One of the foremost drivers of the drug-eluting stents market is the escalating prevalence of cardiovascular diseases (CVDs) globally. Cardiovascular diseases, including coronary artery disease (CAD), heart attacks, and strokes, have become the leading cause of mortality and morbidity worldwide. The increasing incidence of conditions such as diabetes, hypertension, obesity, and sedentary lifestyles contributes to the growing burden of CVDs. The World Health Organization (WHO) reports that approximately 17.9 million people die each year from CVDs, representing 31% of all global deaths. This rising prevalence necessitates effective treatments, and DES, which releases medication to prevent the re-narrowing of arteries, is crucial in managing these conditions. The effectiveness of DES in reducing restenosis rates compared to bare-metal stents has made them a preferred choice in percutaneous coronary interventions (PCIs), thereby driving market growth.
- Advancements in Stent Technology:
Technological advancements in the design and development of drug-eluting stents have significantly propelled the market. Innovations have focused on improving the safety, efficacy, and biocompatibility of stents. The development of next-generation DES involves the use of biodegradable polymers and novel drug coatings, which enhance drug delivery and reduce adverse effects such as late stent thrombosis. Moreover, the introduction of bioresorbable stents, which gradually dissolve after delivering the drug, has garnered attention for their potential to restore natural vessel function and reduce long-term complications. Enhanced stent designs, including thinner struts and improved flexibility, have also facilitated easier implantation and reduced the risk of procedural complications. These technological strides have not only increased the adoption of DES among healthcare professionals but also expanded their application across various patient demographics, thus driving market growth.
- Increasing Awareness and Preference for Minimally Invasive Procedures:
The growing awareness and preference for minimally invasive procedures among patients and healthcare providers have significantly influenced the drug-eluting stents market. Minimally invasive interventions, such as percutaneous coronary interventions, offer several benefits over traditional open-heart surgeries, including shorter hospital stays, reduced recovery times, and lower risk of complications. As a result, there is a rising inclination towards these procedures for treating coronary artery diseases. The effectiveness of DES in preventing restenosis and reducing the need for repeat revascularization procedures has further bolstered their demand. Additionally, the increasing availability of specialized cardiac centers and skilled interventional cardiologists has facilitated the widespread adoption of DES. Public health initiatives and educational campaigns have also played a pivotal role in raising awareness about the advantages of minimally invasive treatments, thereby contributing to the growth of the DES market.
Speak to An Analyst: https://www.imarcgroup.com/request?type=report&id=4815&flag=C
Drug-Eluting Stents Market Report Segmentation:
By Coating:
- Polymer Based Coating
- Polymer Free Coating
Polymer-free coating represents the largest segment due to its reduced risk of late stent thrombosis and better biocompatibility.
By Drug:
- Sirolimus
- Paclitaxel
- Zotarolimus
- Everolimus
- Biolimus
- Others
On the basis of drug, the market has been categorized into sirolimus, paclitaxel, zotarolimus, everolimus, biolimus, and others.
By Stent Platform:
- Stainless-steel
- Cobalt-Chromium
- Platinum-Chromium
- Nitinol
- Others
Cobalt-chromium stents hold the largest market share due to their superior strength, flexibility, and biocompatibility.
By Generation:
- 1st Generation
- 2nd Generation
- 3rd Generation
- 4th Generation
By Application:
- Coronary Artery Disease
- Peripheral Artery Disease
The coronary artery disease sector dominates the market due to the high prevalence and critical need for effective treatment options.
By End User:
- Hospitals
- Ambulatory Surgical Centers
- Others
Hospitals are the biggest end user segment due to their advanced infrastructure and availability of skilled healthcare professionals for performing percutaneous coronary interventions.
Regional Insights:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
By region, North America was the largest market due to the high prevalence of cardiovascular diseases, advanced healthcare infrastructure, and substantial healthcare expenditure.
Global Drug-Eluting Stents Market Trends:
The growth of the drug-eluting stents market is also driven by the increasing investment in healthcare infrastructure, the rise in the geriatric population requiring cardiac care, and supportive government policies and reimbursement schemes that facilitate access to advanced medical treatments for a broader patient population. Besides this, the expansion of healthcare services in emerging economies, rising demand for outpatient procedures, and continuous improvement in post-procedural care and follow-up are creating a positive outlook for market expansion.
Top Companies Operated in Drug-Eluting Stents Industry:
- Abbott Laboratories
- B. Braun Melsungen AG
- Biosensors International Group Ltd.
- Biotronik
- Boston Scientific Corporation
- Cardinal Health Inc.
- Cook Medical LLC (Cook Group Incorporated)
- Lepu Medical Technology (Beijing) Co. Ltd.
- Medtronic plc
- MicroPort Scientific Corporation
- Sino Medical Sciences Technology Inc.
- Terumo Corporation.
Key Highlights of the Report:
- Market Performance (2018-2023)
- Market Outlook (2024-2032)
- Market Trends
- Market Drivers and Success Factors
- Impact of COVID-19
- Value Chain Analysis
- Comprehensive mapping of the competitive landscape
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
